Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.72
-0.49 (-3.45%)
May 15, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 51 employees as of December 31, 2025. The number of employees increased by 10 or 24.39% compared to the previous year.
Employees
51
Change (1Y)
10
Growth (1Y)
24.39%
Revenue / Employee
n/a
Profits / Employee
-$1,145,961
Market Cap
512.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 51 | 10 | 24.39% |
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Ginkgo Bioworks Holdings | 485 |
| ProKidney | 231 |
| Prime Medicine | 146 |
| Upstream Bio | 75 |
| Prothena Corporation | 67 |
| Tectonic Therapeutic | 60 |
| AgomAb Therapeutics NV | 58 |
CTNM News
- 2 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 days ago - Contineum price target raised to $16 from $14 at Morgan Stanley - TheFly
- 5 days ago - Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Business Wire
- 6 days ago - Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 12 days ago - Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 16 days ago - Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Contineum reports positive topline data from exploratory PIPE-791 Phase 1b - TheFly
- 17 days ago - Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - Business Wire